登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，8月14日，A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-08-18

  • A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
    Shipo Wu, Gongxun Zhong, Jun Zhang, Lei Shuai, Zhe Zhang, Zhiyuan Wen, Busen Wang, Zhenghao Zhao, Xiaohong Song, Yi Chen, Renqiang Liu, Ling Fu, Jinlong Zhang, Qiang Guo, Chong Wang, Yilong Yang, Ting Fang, Peng Lv, Jinliang Wang, Junjie Xu, Jianmin Li, Changming Yu, Lihua Hou, Zhigao Bu & Wei Chen
    Nature Communications volume 11, Article number: 4081 (2020)

    Abstract
    The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.

  • 原文来源：https://www.nature.com/articles/s41467-020-17972-1
120浏览量
原文链接
相关报告

  • 《Nature，8月21日，An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-09-02
    • An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques Liqiang Feng, Qian Wang, […]Ling Chen Nature Communications volume 11, Article number: 4207 (2020) Abstract The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 1010 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation.
    93浏览量
    原文链接

  • 《Nature，12月16日，A single dose of recombinant VSV-?G-spike vaccine provides protection against SARS-CoV-2 challenge》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-12-23
    • A single dose of recombinant VSV-?G-spike vaccine provides protection against SARS-CoV-2 challenge Yfat Yahalom-Ronen, Hadas Tamir, […]Tomer Israely Nature Communications volume 11, Article number: 6402 (2020) Abstract The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-?G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and  alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-?G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.
    90浏览量
    原文链接